Toripalimab
Total Neoadjuvant Therapy
Ruijin Hospitalmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Total Neoadjuvant Therapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Serplulimab Tao Zhang | Phase 3 | B |
Eloxatin Tao Zhang | Phase 3 | B |
Capecitabine Tao Zhang | Phase 3 | B |
Same molecule, other indications
Toripalimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →